Abstract
Screening for prostate cancer by use of serum prostate specific antigen (PSA) remains controversial. In the recent Cochrane analysis, an attempt is made to clarify the issue by conducting a meta analysis of available randomized screening trials. Two large trials are considered to provide data of similar and sufficient quality to conduct a separate meta analysis. However, in the view of this author, this analysis fails because standard Cochrand quality criteria are not observed. Details are given and the outcome suggests that one of the trials, the European Randomized Study of Screening for Prostate Cancer (ERSPC) should be considered superior to the Prostate, Lung, Colon, Ovary screening trial (PLCO) conducted in the USA.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ciatto S, Zappa M, Villers A, Paez A, Otto SJ, Auvinen A (2003) Contamination by opportunistic screening in the European randomized study of prostate cancer screening. BJU Int 92(2):97–100
Grubb RL 3rd, Pinsky PF, Greenlee RT, Izmirlian G et al (2008) Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 102(11):1524–1530
Higgins JPT, Green S (eds) (2008) Cochrane handbook for systematic reviews of interventions. Wiley, New York
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) Cochrane bias methods group; cochrane statistical methods group. BMJ 18(343):d5928
Ilic D, Neuberger MM, Djulbegovic M, Dahm P (2013) Screening for prostate cancer. Cochrane Database Syst Rev 1:CD004720
Pinsky PF, Black A, Parnes HL, Grubb R, Crawford DE, Miller A, Reding D, Andriole G (2012) Prostate cancer specific survival in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Cancer Epidemiol 36(6):e401–e406
Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis L, Recker F, Berenguer A, Ruutu M, Kujala P, Bangma CH, Aus G, Tammela TL, Villers A, Rebillard X, Moss SM, de Koning HJ, Hugosson J, Auvinen A (2009) Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European randomized study of screening for prostate cancer (ERSPC). Eur Urol 56(4):584–591
Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366:981–990
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schröder, F.H. (2014). ERSPC, PLCO Studies and Critique of Cochrane Review 2013. In: Cuzick, J., Thorat, M. (eds) Prostate Cancer Prevention. Recent Results in Cancer Research, vol 202. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45195-9_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-45195-9_7
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-45194-2
Online ISBN: 978-3-642-45195-9
eBook Packages: MedicineMedicine (R0)